Author:
Fernandez-Martinez David,Tully Mark D.,Leonard Gordon,Mathieu Magali,Kandiah Eaazhisai
Abstract
AbstractMulti-specific antibodies (msAbs) are being developed as next generation antibody-based therapeutics. Knowledge of the three-dimensional structures, in the full antibody context, of their fragment antigen-binding (Fab) moieties with or without bound antigens is key to elucidating their therapeutic efficiency and stability. However, the flexibility of msAbs, a feature essential for their multi specificity, has hindered efforts in this direction. Cross-Over Dual Variable immunoglobulin (CODVIg) is a promising bispecific antibody format, designed to simultaneously target the interleukins IL4 and IL13. In this work we present the biophysical and structural characterisation of a CODVFab:IL13 complex in the full antibody context, using cryo-electron microscopy at an overall resolution of 4.2 Å. Unlike the 1:2 stoichiometry previously observed for CODVIg:IL4, CODVIg:IL13 shows a 1:1 stoichiometry. As well as providing details of the IL13-CODV binding interface, including the residues involved in the epitope-paratope region, the structure of CODVFab:IL13 also validates the use of labelling antibody as a new strategy for the single particle cryo-EM study of msAbs in complex with one, or more, antigens. This strategy reduced the inherent flexibility of the IL13 binding domain of CODV without inducing either structural changes at the epitope level or steric hindrance between the IL4 and IL13 binding regions of CODVIg. The work presented here thus also contributes to the development of methodology for the structural study of msAbs, a promising platform for cancer immunotherapy.
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Brinkmann, U. & Kontermann, R. E. The making of bispecific antibodies. mAbs 9(182), 212 (2017).
2. Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. W. H. I. Bispecific antibodies: A mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585–608 (2019).
3. Husain, B. & Ellerman, D. Expanding the boundaries of biotherapeutics with bispecific antibodies. BioDrugs 32, 441–464 (2018).
4. Panke, C. Bi- and Multi-specific Antibodies (Technische Universität München, 2015).
5. Brinkmann, U. & Kontermann, R. E. Bispecific antibodies. Science 372, 916–917 (2021).